TISIDB

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm
Domain	PF12796 Ankyrin repeats (3 copies)
Function	Interacts strongly with CDK4 and CDK6 and inhibits them.

> Gene Ontology [ TOP ]
Biological Process	GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000082 G1/S transition of mitotic cell cycle GO:0000731 DNA synthesis involved in DNA repair GO:0001101 response to acid chemical GO:0001558 regulation of cell growth GO:0001933 negative regulation of protein phosphorylation GO:0006469 negative regulation of protein kinase activity GO:0007050 cell cycle arrest GO:0007584 response to nutrient GO:0007605 sensory perception of sound GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0009314 response to radiation GO:0009411 response to UV GO:0009416 response to light stimulus GO:0009991 response to extracellular stimulus GO:0010466 negative regulation of peptidase activity GO:0010951 negative regulation of endopeptidase activity GO:0016049 cell growth GO:0030308 negative regulation of cell growth GO:0031667 response to nutrient levels GO:0032526 response to retinoic acid GO:0033273 response to vitamin GO:0033280 response to vitamin D GO:0033673 negative regulation of kinase activity GO:0042326 negative regulation of phosphorylation GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0045786 negative regulation of cell cycle GO:0045861 negative regulation of proteolysis GO:0045926 negative regulation of growth GO:0048102 autophagic cell death GO:0050954 sensory perception of mechanical stimulus GO:0051346 negative regulation of hydrolase activity GO:0051348 negative regulation of transferase activity GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0071897 DNA biosynthetic process GO:0071900 regulation of protein serine/threonine kinase activity GO:0071901 negative regulation of protein serine/threonine kinase activity GO:0097193 intrinsic apoptotic signaling pathway GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902532 negative regulation of intracellular signal transduction GO:1904029 regulation of cyclin-dependent protein kinase activity GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000117 negative regulation of cysteine-type endopeptidase activity GO:2001020 regulation of response to DNA damage stimulus GO:2001021 negative regulation of response to DNA damage stimulus GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function	GO:0004857 enzyme inhibitor activity GO:0004860 protein kinase inhibitor activity GO:0004861 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity GO:0019207 kinase regulator activity GO:0019210 kinase inhibitor activity GO:0019887 protein kinase regulator activity GO:0030291 protein serine/threonine kinase inhibitor activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04068 FoxO signaling pathway hsa04110 Cell cycle
Reactome	R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-69231: Cyclin D associated events in G1 R-HSA-69236: G1 Phase R-HSA-453279: Mitotic G1-G1/S phases R-HSA-2559585: Oncogene Induced Senescence R-HSA-2559580: Oxidative Stress Induced Senescence R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04068 FoxO signaling pathway
hsa04110 Cell cycle

Reactome

R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-69231: Cyclin D associated events in G1
R-HSA-69236: G1 Phase
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-2559585: Oncogene Induced Senescence
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CDKN2D and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CDKN2D in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CDKN2D in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.743	0.0231
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.586	0.757
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.852	0.519
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.313	0.354
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.035	0.971
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.663	0.557
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.064	0.848
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.264	0.787
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.181	0.863
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.439	0.138
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.94	0.552
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.07	0.513

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CDKN2D in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDKN2D. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDKN2D. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDKN2D. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDKN2D. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CDKN2D expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CDKN2D and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CDKN2D
Name	cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
Aliases	INK4D; p19-INK4D; CDK inhibitor p19INK4d; cell cycle inhibitor, Nur77 associating protein; cyclin-dependent ......
Chromosomal Location	19p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CDKN2D collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CDKN2D